June 15, 2020 / 1:03 PM / 24 days ago

BRIEF-Cardiff Oncology Says Data Demonstrate Efficacy, Durability And Safety Of Onvansertib

June 15 (Reuters) - Cardiff Oncology Inc:

* CARDIFF ONCOLOGY DATA CONTINUES TO DEMONSTRATE EFFICACY, DURABILITY AND SAFETY OF ONVANSERTIB IN PATIENTS WITH DIFFICULT-TO-TREAT RELAPSED/REFRACTORY AML

* CARDIFF ONCOLOGY INC - ANTI-LEUKEMIC ACTIVITY WAS OBSERVED AT A WIDE RANGE OF ONVANSERTIB DOSES IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below